Neodynamic Q2: Commercialization temporarily on hold - Redeye

Redeye returns with a more detailed take on the Q2 report and concludes that the slow sales ramp-up is likely to spill over onto next year, by when FDA approval should be in place, opening the door for more substantial long-term sales growth. We also expect an equity issue by late H1 2023 rather than late 2023/early 2024 and have adjusted our fair value range according to our capital raise assumptions.

Länk till analysen i sin helhet: https://www.redeye.se/research/852207/q2-2022-commercialization-temporarily-on-hold?utm_source=finwire&utm_medium=RSS